Clinical trials: Placebo Group
Type 2 Diabetes
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
- Trial name
- NCT00614939
- Testing
- Saxagliptin
- Where
- 74 sites in United States, Belarus and 12 more
- Volunteers
- 572 people
- Sponsor
- AstraZeneca
Cystic Fibrosis
Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
This study will evaluate the efficacy and safety of CTP-656 in patients with cystic fibrosis (CF) who have a cystic fibrosis transmembrane conductance regulator (CFTR) gating mutation.
- Trial name
- NCT02971839
- Testing
- VX-561, IVA
- Where
- 14 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Facial Angiofibroma, Tuberous Sclerosis
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
The study aims to compare the safety and efficacy of two different strengths of Rapamycin cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (FA) associated with Tuberous Sclerosis Complex (TSC).
- Trial name
- NCT03826628
- Testing
- rapamycin
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 107 people
- Sponsor
- Dermatology Specialties Limited Partnership
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
- Trial name
- NCT03310580
- Testing
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 40 sites in United States
- Volunteers
- 42 people
- Sponsor
- Aerie Pharmaceuticals
Episodic Migraine
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03777059
- Testing
- Atogepant
- Where
- 138 sites in United States
- Volunteers
- 910 people
- Sponsor
- Allergan
Lambert-Eaton Myasthenic Syndrome
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during…
- Trial name
- NCT02970162
- Testing
- Amifampridine Phosphate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Rheumatoid Arthritis
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
This is a sub-study of the OSKIRA-4 study, (D4300C0004, NCT01264770) to explore alternative and more sensitive modalities for measuring the beneficial effects of syk inhibition with fostamatinib in patients with active RA.
- Trial name
- OSKIRA 4 SS (NCT02092961)
- Testing
- Fostamatinib, Adalimumab
- Where
- 21 sites in United States, Bulgaria and 9 more
- Volunteers
- 198 people
- Sponsor
- AstraZeneca
Chronic Constipation
Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC).
- Trial name
- NCT00765882
- Testing
- Linaclotide 290 micrograms, Linaclotide 145 micrograms
- Where
- 108 sites in United States, Canada
- Volunteers
- 633 people
- Sponsor
- Forest Laboratories
Acute Post-surgical Pain
Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.
This is a Phase 3, randomized, double-blind, controlled, parallel-group, multicenter clinical trial with co-crystal E-58425 compared to tramadol, to celecoxib, and to placebo.
- Trial name
- NCT03108482
- Testing
- Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®)
- Where
- 5 sites in United States
- Volunteers
- 637 people
- Sponsor
- Esteve Pharmaceuticals, S.A.
Endometriosis
Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb
The purpose of this study is to assess safety and efficacy of BAY 1817080 compared to elagolix and placebo in women with symptomatic endometriosis.
- Trial name
- SCHUMANN (NCT04614246)
- Testing
- BAY1817080, Elagolix
- Where
- 147 sites in United States, Austria and 18 more
- Volunteers
- 215 people
- Sponsor
- Bayer
Dermatomyositis
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants…
- Trial name
- NCT04999020
- Testing
- Ravulizumab
- Where
- 111 sites in United States, Australia and 11 more
- Volunteers
- 38 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Colitis, Ulcerative
Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
The purpose of the study was to assess preliminary efficacy, safety, and tolerability of LYS006 in adult patients with mild to moderate ulcerative colitis and to determine if LYS006 has an adequate clinical profile for further…
- Trial name
- NCT04074590
- Testing
- LYS006
- Where
- 9 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without metformin over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-L (NCT00715624)
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 496 people
- Sponsor
- Sanofi
Urinary Bladder, Overactive
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
Patients with overactive bladder are often treated with tolterodine, a medication that helps relax the bladder, helping symptoms of urinary incontinence and urinary frequency.
- Trial name
- NCT01302054
- Testing
- Fesoterodine 8 mg
- Where
- 176 sites in United States, Bulgaria and 13 more
- Volunteers
- 990 people
- Sponsor
- Pfizer
Chronic Rhinosinusitis
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with…
- Trial name
- NCT03960580
- Testing
- OPN-375
- Where
- 87 sites in United States, Australia and 8 more
- Volunteers
- 223 people
- Sponsor
- Optinose US Inc.
Irritable Bowel Syndrome With Diarrhea
Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-2 (NCT01303224)
- Testing
- Ibodutant
- Where
- 71 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 565 people
- Sponsor
- Menarini Group
Osteoarthritis of the Knee
Gel-200 Versus Placebo in Osteoarthritis of the Knee
The purpose of this study is to determine if a single intra-articular injection of Gel-200 is superior to a single injection of Phosphate Buffered Saline (PBS) in subjects with symptomatic osteoarthritis of the knee.
- Trial name
- NCT00449696
- Testing
- Gel-200
- Where
- United States
- Volunteers
- 379 people
- Sponsor
- Seikagaku Corporation
Alzheimer Disease
Study of ASN51 in Adults With Early Alzheimer's Disease
The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of…
- Trial name
- NCT06677203
- Testing
- ASN51
- Where
- 7 sites in United States
- Volunteers
- 123 people
- Sponsor
- Asceneuron S.A.
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)
The primary objective of this study is to evaluate the efficacy of a 200 micrograms (mcg) dose of CEP-33457 compared with placebo in participants with active systemic lupus erythematosus (SLE) as assessed by the proportion of…
- Trial name
- NCT01135459
- Testing
- CEP-33457
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 183 people
- Sponsor
- Cephalon, Inc.
Type II Diabetes Mellitus
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus
The purpose of this study is: to assess clinical efficacy of Subetta in the combined treatment of type II diabetes mellitus; to assess safety of Subetta in the combined treatment of type II diabetes mellitus.
- Trial name
- NCT01868646
- Testing
- Subetta
- Where
- 17 sites in Russia
- Volunteers
- 190 people
- Sponsor
- Materia Medica Holding
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.